Drug intelligence / Profile preview

bevacizumab + docetaxel + pemetrexed

Development stage: Preclinical
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of bevacizumab (an anti-VEGF monoclonal antibody), docetaxel (a taxane-based chemotherapy), and pemetrexed (a folate analog). This triple combination targets multiple pathways in cancer treatment: bevacizumab inhibits angiogenesis by targeting VEGF-A, docetaxel disrupts cell division by stabilizing microtubules, and pemetrexed inhibits folate-dependent enzymes involved in DNA synthesis. The combination has been studied primarily for non-small cell lung cancer (NSCLC) treatment.

Targets

GART (GAR transformylase)VEGFA (Vascular endothelial growth factor A)MicrotubuleDHFR (Dihydrofolate reductase)TS (Thymidylate synthase)

Beyond the preview

Go deeper on bevacizumab + docetaxel + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + docetaxel + pemetrexed.

Explore the full profile